Herpes Zoster in Kidney Transplant Recipients: Detection of VZV DNA in Blood During the Prodromal Phase

Anne Devin, MD,1 Edith Renoult, MD,1 Michel Roger, MD,2 and Marie-Josée Hébert, MD1

Herpes zoster (HZ) usually begins with radicular pain in 1 to 3 dermatomes followed by the appearance of a vesicular eruption over the affected area. In transplant recipients who are at high risk of life-threatening visceral dissemination of varicella zoster virus (VZV), neuropathic pain (the prodrome) may precede the appearance of a rash by weeks and shingles may be absent.1 We aimed to investigate whether VZV DNA detection in plasma could have value for an early diagnosis of HZ during the prodromal phase.

We evaluated 11 kidney transplant recipients who developed HZ in the first year after transplantation and from whom 2 to 7 blood samples had been systematically collected in the first 6 months and stored in our transplant biobank, approved by the local Institutional Review Board (BH 07-002). Plasma VZV DNA was retrospectively analyzed by a qualitative real-time PCR analysis2 of these stored samples.

The 11 subjects (Table 1) underwent transplantation between 2009 and 2013. The mean time from transplantation to the onset of shingles was 129 days (range, 12-307 days). Prodromal symptoms occurred at 5.5 days on average (range, 0-19 days) before skin eruptions. A total of 41 blood samples from our study cohort were available for analysis, at a median of 4 specimens per patient. Plasma VZV DNA was produced in 7 individuals. It was detected during HZ infection, at 2 to 53 days after rash onset, in 3 patients. Varicella zoster virus replication was also noted during the prodromal phase, in 1 of these 3 subjects (patient 10, who was diagnosed with HZ ophthalmicus 6 days later) and in another recipient (patient 8, who developed VZV vasculopathy 12 days later).

Our retrospective analysis of available archived blood specimens in a small number of patients had obvious limitations but our findings provide interesting PCR evidence of VZV reactivation during HZ in transplant recipients. These data document the presence of VZV in the plasma of 4 patients diagnosed with HZ. In 3 of these cases, VZV DNA was detectable in blood taken up to 53 days after the onset of shingles. Blood VZV DNA has previously been detected during acute HZ,3,4 in 16% to 100% of the patient populations analyzed by molecular assays. Some previous studies have revealed a higher VZV load in immunocompromised patients. In addition, VZV DNAemia can be documented up to 6 months after skin eruptions. An even more interesting observation from our results was the detection of VZV DNA before rash onset in 2 individuals. In both of these patients, the prodromal phase was particularly painful and prolonged, and the clinical features of HZ were quite severe, particularly in 1 patient who developed a VZV vasculopathy as described elsewhere.5 Analysis of VZV DNA in plasma could therefore be used for the early diagnosis of atypical HZ and avoid delayed initiation of treatment. However, the precise diagnostic value of this marker for these purposes requires additional research.6

REFERENCES

1. Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):135–146.
2. Weidmann M, Meyer-König U, Hufert FT. Rapid detection of Herpes simplex virus and varicella-zoster virus infections by real-time PCR. J Clin Virol. 2003;41:1565–1568.
3. Levin MJ. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol. 2014;61:487–495.
4. Park SY, Kim JY, Kim JA, et al. Diagnostic usefulness of varicella-zoster virus real-time polymerase chain reaction analysis of DNA in saliva and plasma specimens from patients with herpes zoster. J Infect Dis. 2017;217:51–57.
5. Renoult E, Lantier S, Rouleau D, et al. Varicella zoster virus vasculopathy after kidney transplantation. Transplantation. 2016;100:e19–e20.
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|---------|---|---|---|---|---|---|---|---|---|----|----|
| Age, y  | 47 | 51 | 56 | 62 | 61 | 72 | 51 | 65 | 36 | 52 | 67 |
| Sex     | M  | F  | M  | M  | F  | M  | M  | F  | M  | M  | M  |
| VZV serology (IgG titre) | + (ND) | + (ND) | + (ND) | + (2.84) | + (1.86) | + (3.41) | + (ND) | + (1.53) | + (1.43) | + (ND) | + (>1.1) |
| At transplant | + (2.74) | + (2.3) | + (ND) | + (2.51) | + (1.88) | + (2.16) | + (3.10) | – (0.70) | + (1.60) | + (3.1) | + (>1.1) |
| CMV serostatus D/R | –/– | –/– | +/+ | –/+ | +/+ | –/+ | –/+ | –/+ | –/+ | –/+ | –/+ |
| Antiviral prophylaxis | None | None | Yes | None | None | None | None | None | None | None | None |
| Days between transplant and prodrome onset | 22 | 126 | 227 | 12 | 131 | 177 | 302 | 18 | 188 | 22 | 110 |
| Days between prodrome onset and skin rash | 2 | 4 | 7 | 0 | 2 | 0 | 5 | 16 | 7 | 1 | 1 |
| VZV replication | Time c (result) | 1 (negative) | 27 (negative) | 1 (negative) | 0 (negative) | 0 (negative) | 34 (negative) | 0 (negative) | 3 (negative) | 48 (negative) | 0 (negative) | 5 (negative) |
| Time c (result) | 13 (negative) | 79 (negative) | 8 (negative) | 28 (negative) | 33 (negative) | 91 (negative) | 30 (negative) | 28 (negative) | 97 (negative) | 9 (negative) | 35 (negative) |
| Time c (result) | 26 (positive) | 163 (negative) | 27 (negative) | 82 (negative) | 209 (negative) | 93 (negative) | 167 (negative) | 29 (positive) | 89 (negative) | 184 (negative) | 49 (positive) | 179 (negative) |
| Time c (result) | 183 (positive) | 35 (negative) | 89 (negative) | 18 (negative) | 84 (negative) | 91 (negative) | 189 (negative) | 91 (negative) | 189 (negative) | 84 (negative) | 91 (negative) |
| VZV presentation | Single dermatome | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Contiguous dermatomes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Generalized HZ (skin) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Ophthalmic zoster | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| VZV vasculopathy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

*In accordance with manufacturer’s instructions, a test value of at least 1.1 is considered positive.

**CMV prophylaxis with valganciclovir during the first 100 days after transplantation.

---

CMV, cytomegalovirus; D, donor; M, male; F, female; ND, no data; R, recipient.